Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024


Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 663066, or from the webcast link in the investor relations section of the company's website at www.revance.com.

A webcast replay will be available beginning May 9, 2024, at 4.30 p.m. PT / 7.30 p.m. ET to August 9, 2024, at 4.30 p.m. PT / 7.30 p.m. ET. To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance's portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.

Revance's global headquarters and experience center is located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn.

"Revance", the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA.


These press releases may also interest you

at 05:02
The Future is Now: Companion Diagnostics Market to Surge to $15.4 Billion by 2028
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...

at 05:00
WellSync Powers The Vitamin Shoppe's New Whole Health Rx Telehealth Service
WellSync, an API-driven virtual care service provider, today announced its partnership with The Vitamin Shoppe to launch Whole Health Rx, a cutting-edge telehealth service providing access to GLP-1 medications for weight management. WellSync provides...

at 04:00
Philips presents study results at Heart Rhythm Annual Meeting demonstrating benefits of its AI-powered cardiac monitoring solutions
May 17, 2024 Three studies demonstrate how Philips MCOT wearable ambulatory monitoring ECG and proprietary AI models applied to ECG digital biomarkers can help to improve diagnosis, reduce readmissions, and lower costs Amsterdam, the Netherlands...

at 04:00
Brainomix Achieves Breakthrough with FDA Clearance of e-Lung AI Software
Brainomix, a pioneer in artificial intelligence (AI) imaging solutions to enable precision medicine, is proud to announce the FDA clearance of...

at 04:00
OMRON Healthcare's Presence at Heart Rhythm 2024 in the U.S.
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announced its presence at Heart Rhythm 2024, the Annual Meeting of the Heart Rhythm Society (HRS) in the U.S. At Heart Rhythm 2024, the Company will showcase its upper-arm blood...

at 03:00
Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwide.  Hypertension is known as the "silent killer" because many people do not know they have it and, over time, it can lead...

More news about Health...


News published on and distributed by: